Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 43-52

  Cho, William C S ^a   Yip, Timothy T C ^a   Yip, Christine ^b   Yip, Victor ^b   Thulasiraman, Vanitha ^b   Ngan, Roger K C ^a   Yip, Tai Tung ^b   Lau, Wai Hon ^a   Au, Joseph S K ^a   Law, Stephen C K ^a   Cheng, Wai Wai ^a   Ma, Victor W S ^a   Lim, Cadmon K P ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CISPLATIN; DEXAMETHASONE; GEMCITABINE; ISOPROTEIN; METOCLOPRAMIDE; PROTEOME; TRYPTASE; TUMOR MARKER; VIRUS DNA;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; EVALUATION; FEMALE; FOLLOW UP; HONG KONG; HUMAN; IMMUNOASSAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NASOPHARYNX CANCER; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEOMICS; RADIATION DOSE; RELIABILITY; SALVAGE THERAPY; TANDEM MASS SPECTROMETRY; THYROTOXICOSIS;

ADULT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HONG KONG; HUMANS; LONGITUDINAL STUDIES; LUNG; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PROTEOME; PROTEOMICS; REMISSION INDUCTION; SERUM AMYLOID A PROTEIN; THYROTOXICOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 1642453766     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0413-3     Document Type: Article

References (46)

1. Hong Kong Hospital Authority. Cancer Incidence and Mortality in Hong Kong 1998-1999. Hong Kong Cancer Registry, pp. 38-39, 2000.
2. Ho, J. H. C. Nasopharyngeal carcinoma (NPC). Adv. Cancer Res., 15: 57-92, 1972.
3. Lee, A. W., Poon, Y. F., Foo, W., Law, S. C., Cheung, F. K., Chan, D. K., Tung, S. Y., Thaw, M., and Ho, J. H. C. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys., 23: 261-270, 1992.
4. Leung, S. F., Teo, P. M., Shiu, W. W., Tsao, S. Y., and Leung, T. W. Clinical features and management of distant metastases of nasopharyngeal carcinoma. J. Otolaryngol., 20: 27-29, 1991.
5. Ngan, R. K. C., Lau, W. H., Yip, T. T. C., Cho, W. C. S., Cheng, W. W., Lim, C. K., Wan, K. K., Chu, E., Joab, I., Grunewald, V., Poon, Y. F., and Ho, J. H. C. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann. N Y Acad. Sci., 945: 73-79, 2001.
6. Ngan, R. K. C., Yip, T. T. C., Cheng, W. W., Chan, J. K. C., Cho, W. C. S., Ma, V. W. S., Wan, K. K., Au, S. K., Law, C. K., and Lau, W. H. Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. Clin. Cancer Res., 8: 986-994, 2002.
7. Fung, E. T., Thulasiraman, V., Weinberger, S. R., and Dalmasso, E. A. Protein biochips for differential profiling. Curr. Opin. Biotechnol., 12: 65-69, 2001.
8. Petricoin, E. F., III, Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577, 2002.
9. Poon, Y. F., and Lau, W. H. Current management of carcinoma of the nasopharynx. In: J. S. Tobias and P. R. M. Thomas (eds.), Current Radiation Oncology, Vol. 3, pp. 146-176. New York: Oxford University Press, 1998.
10. Ngan, R. K., Yiu, H. H., Lau, W. H., Yau, S., Cheung, F. Y., Chan, T. M., Kwok, C. H., Chiu, C. Y., Au, S. K., Foo, W., Law, C. K., and Tse, K. C. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a Phase II study. Ann. Oncol., 13: 1252-1258, 2002.
11. Hutches, T. W., and Yip, T. T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom., 7: 576-580, 1993.
12. Cleveland, D. W., Fischer, S. G., Kirschner, M. W., and Laemmli, U. K. Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J. Biol. Chem., 252: 1102-1106, 1977.
13. Baudys, M., Foundling, S., Pavlik, M., Blundell, T., and Kostka, V. Protein chemical characterization of Mucor pusillus aspartic proteinase amino acid sequence homology with the other aspartic proteinases disulfide bond arrangement and site of carbohydrate attachment. FEBS Lett., 235: 271-274, 1988.
14. Fournier, I., Chaurand, P., Bolbach, G., Lutzenkirchen, F., Spengler, B., and Tabet, J. C. Sequencing of a branched peptide using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J. Mass Spectrom., 35: 1425-1433, 2000.
15. Perkins, D. N., Pappin, D. J., Creasy, D. M., and Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis, 20: 3551-3567, 1999.
16. Fung, E., and Enderwich, C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques, 32: S34-S41, 2002.
17. Krauth, J. The interpretation of significance tests for independent and dependent samples. J. Neurosci. Methods, 9: 269-281, 1983.
18. Ho, J. H. C. Stage classification of nasopharyngeal carcinoma: a review. In: G. De The and Y. Eto (eds.), Nasopharyngeal Carcinoma: Etiology and Contro. IARC Scientific Publ. No. 20, pp. 99-113. Lyon, France: IARC, 1978.
19. Lo, Y. M., Chan, L. Y., Lo, K. W., Leung, S. F., Zhang, J., Chan, A. T., Lee, J. C., Hjelm, N. M., Johnson, P. J., and Huang, D. P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 59: 1188-1191, 1999.
20. Wright, G. L., Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn., 2: 549-563, 2002.
21. Issaq, H. J., Veenstra, T. D., Conrads, T. P., and Felschow, D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun., 292: 587-592, 2002.
22. Weinberger, S. R., Dalmasso, E. A., and Fung, E. T. Current achievements using ProteinChip Array technology. Curr. Opin. Chem. Biol., 6: 86-91, 2002.
23. Xiao, Z., Adam, B. L., Cazares, L. H., Clements, M. A., Davis, J. W., Schelhammer, P. F., Dalmasso, E. A., and Wright, G. L., Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res., 61: 6029-6033, 2001.
24. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schelhammer, P. F., Yasui, Y., Feng, Z., and Wright, G. L. Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614, 2002.
25. Wu, W., Tang, X., Hu, W., Lotan, R., Hong, W. K., and Mao, L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin. Exp. Metastasis, 19: 319-326, 2002.
26. Valle, R. P., Chavany, C., Zhukov, T. A., and Jendoubi, M. New approaches for biomarker discovery in lung cancer. Expert Rev. Mol. Diagn., 3: 55-67, 2003.
27. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., and Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem., 48: 1296-1304, 2002.
28. Paweletz, C. P., Trock, B., Pennanen, M., Tsangaris, T., Magnant, C., Liotta, L. A., and Petricoin, E. F., III. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers, 17: 301-307, 2001.
29. Rosty, C., Christa, L., Kuzdzal, S., Baldwin, W. M., Zahurak, M. L., Carnot, F., Chan, D. W., Canto, M., Lillemoe, K. D., Cameron, J. L., Yeo, C. J., Hruban, R. H., and Goggins, M. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res., 62: 1868-1875, 2002.
30. Ardekani, A. M., Liotta, L. A., and Petricoin, E. F., III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev. Mol. Diagn., 2: 312-320, 2002.
31. Yamada, T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin. Chem. Lab. Med., 37: 381-388, 1999.
32. Watson, G., See, C. G., and Woo, P. Use of somatic cell hybrids and fluorescence in situ hybridization to localize the functional serum amyyoid A (SAA) genes to chromosome 11p15.4-p15.1 and the entire SAA superfamily to chromosome 11p15. Genomics, 23: 694-696, 1994.
33. Raynes, J. G., Eagling, S., and McAdam, K. P. Acute-phase protein synthesis in human hepatoma cells. Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin. Exp. Immunol., 83: 488-491, 1991.
34. Bausserman, L. L., Herbert, P. N., Rodger, R., and Nicolosi, R. J. Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim. Biophys. Acta, 792: 186-191, 1984.
35. d'Eril, G. M., Anesi, A., Maggiore, M., and Leoni, V. Biological variation of serum amyloid A in healthy subjects. Clin. Chem., 47: 1498-1499, 2001.
36. Kimura, M., Tomita, Y., Imai, T., Saito, T., Katagiri, A., Ohara-Mikami, Y., Matsudo, T., and Takahashi, K. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer (Phila.), 92: 2072-2075, 2001.
37. Glojnaric, I., Casl, M. T., Simic, D., and Lukac, J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin. Chem. Lab. Med., 39: 129-133, 2001.
38. Biran, H., Friedman, N., Neumann, L., Pras, M., and Shainkin-Kestenbaum, R. Serum amyloid A (SAA) variations in patients with cancer correlation with disease activity, stage, primary site, and prognosis. J. Clin. Pathol., 39: 794-797, 1986.
39. Kaneti, J., Winikoff, Y., Zimlichman, S., and Shainkin-Kestenbaum, R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol. Res., 12: 239-241, 1984.
40. Weinstein, P. S., Skinner, M., Sipe, J. D., Lokich, J. J., Zamcheck, N., and Cohen, A. S. Acute phase proteins of tumor markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand. J. Immunol., 19: 193-198, 1984.
41. Benson, M. D., and Cohen, A. S. Serum amyloid A protein in amyloidosis, rheumatic and neoplastic diseases. Arthritis Rheum., 22: 36-42, 1979.
42. Rosenthal, C. J., and Sullivan, L. M. Serum amyloid A to monitor cancer dissemination. Ann. Inter. Med., 91: 383-390, 1979.
43. Schmidt, U., Wagner, H., and Miethke, T. CpG-DNA upregulates the major acute-phase proteins SAA and SAP. Cell. Microbiol., I: 61-67, 1999.
44. Huang, D. P., Ho, J. H. C., Chan, W. K., Lau, W. H., and Lui, M. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int. J. Cancer, 43: 936-939, 1989.
45. Yip, T. T. C., Ngan, R. K. C., Lau, W. H., Poon, Y. F., Joab, I., Cochet, C., and Cheng, A. K. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer (Phila.), 74: 2414-2424, 1994.
46. Yip, T. T. C., Lau, W. H., Chan, J. K. C., Ngan, R. K. C., Poon, Y. F., Lung, C. W., Lo, T. Y., and Ho, J. H. C. Prognostic significance of DNA flow cytometric analysis in patients with nasopharyngeal carcinoma. Cancer (Phila.), 83: 2284-2292, 1998.